Evaluation of pharmacologic therapies accompanied by behavioural therapy on smoking cessation success: a prospective cohort study in Turkey

Basit Öğe Kaydı
dc.contributor.authorMarakoglu, Kamile
dc.contributor.authorKargin, Nisa Cetin
dc.contributor.authorUcar, Rahime Merve
dc.contributor.authorKizmaz, Muhammet
dc.date.accessioned2020-03-26T19:41:44Z
dc.date.available2020-03-26T19:41:44Z
dc.date.issued2017
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractOBJECTIVE: The main objective of this study is to compare the rate of smoking cessation in the first month, third month, sixth month, first-year, and second year among those who quit smoking following different pharmacological and behavioural therapies administered at the Selcuk University's Smoking Cessation Clinic in Turkey. METHODS: In this study, 3322 people who presented to the clinic in order to quit smoking were advised one of the most suitable medical treatments (varenicline, bupropion, NRT) accompanied by behaviour therapy after their health queries and examinations were made and Fagerstrom scores were evaluated. Smoking cessation patients were followed up clinically and by making calls after smoking cessation. RESULTS: The smoking cessation success rate in the cases using varenicline in the first month was 63.5% (766/1206), in the third month 46.8% (548/1170), in the sixth month 32.1% (386/1201), first year 25.6% (298/1163), and 19.9% (211/1059) in the second year. The success rate in the cases using bupropion in the first month was 49.9% (559/1120), in the third month 35.6% (405/1138), in the sixth month 26.4% (319/1210), first year 21.9% (261/1192), and 16.0% (133/832) in the second year. The success rate in the cases using NRT was 53.2% (25/47) in the first-month, 24.3% (9/37) in the third-month, and 27.3% (6/22) in the sixth-month assessments. The rates of smoking cessation in the cases using varenicline and behavioural therapy in the 1st, 3rd, 6th, 12th, and 24th month were significantly higher compared to the cases using bupropion and behavioural therapy (p =.000, p =.000, p =.008, p =.034, and p =.028; respectively). CONCLUSIONS: It has been observed in this study that varenicline as a smoking cessation drug is better tolerated than other medications and it seems to be more effective.en_US
dc.identifier.doi10.1080/24750573.2017.1342751en_US
dc.identifier.endpage233en_US
dc.identifier.issn2475-0573en_US
dc.identifier.issn2475-0581en_US
dc.identifier.issue3en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage227en_US
dc.identifier.urihttps://dx.doi.org/10.1080/24750573.2017.1342751
dc.identifier.urihttps://hdl.handle.net/20.500.12395/35100
dc.identifier.volume27en_US
dc.identifier.wosWOS:000407497300004en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTAYLOR & FRANCIS LTDen_US
dc.relation.ispartofPSYCHIATRY AND CLINICAL PSYCHOPHARMACOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectSmoking cessationen_US
dc.subjectvareniclineen_US
dc.subjectbupropionen_US
dc.titleEvaluation of pharmacologic therapies accompanied by behavioural therapy on smoking cessation success: a prospective cohort study in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu